Dyslexia Treatment Market - Forecast to 2027

As per the MRFR analysis, the global dyslexia treatment market is projected to register a significant market expansion at a notable CAGR of 7.10% during the review period to surpass USD 38,514.67 million by the end of 2027. Research has shown that dyslexia happen due to the way the brain cerebrum processes data. So that is the reason perusing seems like such sluggish, difficult work. Individuals with dyslexia frequently track down ways of working around their handicap, so nobody will realize they're having trouble. This might save some humiliation, however, getting help could make school and peruse more straightforward. The vast majority are analyzed as children, yet it's to be expected for youngsters or even grown-ups to be analyzed.

The global dyslexia treatment market is expected to register a healthy market expansion owing to the highest market value of USD 23,682.69 million in 2020. The development of the worldwide dyslexia treatment market is driven by the rising predominance of dyslexia and expanding application improvement exercises to treat dyslexia and among others. However, it may, the absence of mindfulness about dyslexia, its side effects, and underdiagnosis is a limiting element for the dyslexia treatment market. Then again, coordinated effort with schools, universities, and non-benefit associations gives rewarding open doors to players working in the worldwide dyslexia treatment market.

Market Segmentation

The global Dyslexia Treatment Market has been classified in terms of type, application, end-user, and region.

The type of segment categorizes the market into Phonological Dyslexia, Surface Dyslexia, and Others. Based on Application, the market is bifurcated into Treatment and Diagnosis. The end-user segment has been classified in terms of Specialty centers, Home Care, Hospitals & Clinics, and Others.

Regional Analysis

The global dyslexia treatment market is classified, geographically into five major regions North America, Europe, Asia-Pacific, and the Rest of the World.

North America represented the biggest market portion of 5.79% is because of the presence of created medical services framework, positive government approaches, and presence of significant key organizations central command in the region, for example, Jubilant Cadista (US) and Speechify (US), and high predominance of dyslexia are driving the market in the area. For example, as per the Dyslexia Center of Utah, one of every five understudies, i.e., 15%-20% of the US populace, have a learning-based incapacity, most regularly dyslexia.

Europe represented a considerable share of the worldwide dyslexia treatment and analysis market. Like North America, Europe additionally faces a high commonness of dyslexia. Asia-Pacific is the quickest developing territorial market for the dyslexia treatment and conclusion market as it is growing quickly and has seen the rise of numerous players. There is likewise a high predominance of dyslexia driving the market development. As indicated by the Department of Biotechnology, in 2019, around 35 million kids in India were thought to be dyslexics. Moreover, provinces in the Asia-Pacific locales have additionally fostered their own dyslexia evaluation tests to accurately recognize the dyslexic populace inside the nation and give proper consideration.

Major Players

The key Companies mentioned in the dyslexia treatment market are Pfizer, Inc. (US), Novartis AG (Switzerland), Lyfta (UK), GlaxoSmithKline (UK), Teva Pharmaceutical Industries Ltd (Israel), Speechify Inc. (US), Jubilant Pharma Limited (Singapore), Lingit AS (Norway), Soli (UK), Eli Lilly & Company (US), RPG Life Sciences Ltd (India), Hopalai D.O.O. (Slovenia).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Product Code: MRFR/HC/6890-CR | March 2022

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW
4.2 DRIVERS
- 4.2.1 INCREASING PREVALENCE OF DYSLEXIA
- 4.2.2 INCREASING APP DEVELOPMENT ACTIVITIES TO TREAT DYSLEXIA
- 4.2.3 GROWING NUMBER OF VITUAL REALITY-BASED EDUCATIONAL SOFTWARE
4.3 RESTRAINT
- 4.3.1 LACK OF AWARENESS ABOUT DYSLEXIA, ITS SYMPTOMS AND UNDERDIAGNOSIS
4.4 OPPORTUNITY
- 4.4.1 COLLABORATION WITH SCHOOLS, COLLEGES AND NON PROFIT ORGANIZATIONS

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 RESEARCH & DEVELOPMENT
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION
- 5.1.4 MARKETING & SALES
- 5.1.5 POST-SALES MONITORING
- 5.1.6 INPUTS
- 5.1.7 SOFTWARE DEVELOPMENT PROCESSES
- 5.1.8 OUTPUT
- 5.1.9 MARKETING AND DISTRIBUTION
- 5.1.10 POST-SELLING SERVICES
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 BARGAINING POWER OF BUYERS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF NEW ENTRANTS
- 5.2.4 THREAT OF SUBSTITUTES
- 5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19
5.4 DYSLEXIA DIAGNOSIS
5.5 DYSLEXIA TREATMENT
5.6 STANDARD PAPER TESTS VS ELECTRONIC VERSIONS
- 5.6.1 TESTS FOR DYSLEXIA AND LEARNING DISABILITIES (PRE-SCHOOLERS)

6 GLOBAL DYSLEXIA TREATMENT & DIAGNOSIS MARKET BY TYPE

6.1 OVERVIEW
6.2 PHONOLOGICAL DYSLEXIA
6.3 SURFACE DYSLEXIA
6.4 OTHERS

7 GLOBAL DYSLEXIA TREATMENT & DIAGNOSIS MARKET BY TREATMENT & DIAGNOSIS

7.1 OVERVIEW
7.2 TREATMENT
- 7.2.1 MEDICATIONS
  - 7.2.1.1 ANTIHISTAMINES
  - 7.2.1.2 CENTRAL NERVOUS STIMULANT
  - 7.2.1.3 ANTI-MYOCLONIC
  - 7.2.1.4 ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) DRUG
  - 7.2.1.5 OTHERS
- 7.2.2 TOOLS
  - 7.2.2.1 E-READERS AND TABLETS
  - 7.2.2.2 APPS
  - 7.2.2.3 SMARTPENS
  - 7.2.2.4 OTHERS
7.3 DIAGNOSIS
- 7.3.1 PAPER-BASED
- 7.3.2 DIGITAL-BASED

8 GLOBAL DYSLEXIA TREATMENT & DIAGNOSIS MARKET BY END USER

8.1 OVERVIEW
8.2 SPECIALTY CENTER
8.3 HOME CARE
8.4 HOSPITALS & CLINICS
8.5 OTHERS

9 GLOBAL DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY REGION

9.1 OVERVIEW
9.2 NORTH AMERICA
- 9.2.1 US
- 9.2.2 CANADA
9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.2 UK
- 9.3.3 FRANCE
- 9.3.4 ITALY
- 9.3.5 SPAIN
- 9.3.6 REST OF EUROPE
9.4 ASIA PACIFIC
- 9.4.1 CHINA
- 9.4.2 JAPAN
- 9.4.3 INDIA
- 9.4.4 AUSTRALIA
- 9.4.5 SOUTH KOREA
- 9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
- 9.5.1 LATIN AMERICA
- 9.5.2 MIDDLE EAST
- 9.5.3 AFRICA

10 COMPETITIVE LANDSCAPE

10.1 COMPETITIVE OVERVIEW
10.2 MAJOR PLAYERS IN THE GLOBAL DYSLEXIA TREATMENT MARKET
10.3 MAJOR GROWTH STRATEGIES IN THE GLOBAL DYSLEXIA TREATMENT MARKET
10.4 COMPETITIVE BENCHMARKING
10.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL DYSLEXIA TREATMENT MARKET
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.6.1 NEW PRODUCT DEVELOPMENTS/LAUNCHES
- 10.6.2 COLLABORATIONS/EXPANSIONS/PARTNERSHIPS/INVESTMENTS
10.7 MAJOR PLAYERS FINANCIAL MATRIX
- 10.7.1 REVENUE OF MAJOR PLAYERS, 2020
- 10.7.2 R&D EXPENDITURE, 2020

11 COMPANY PROFILES

11.1 PFIZER INC.
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCTS OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGIES
11.2 SPEECHIFY INC.
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCTS OFFERED
- 11.2.4 KEY DEVELOPMENTS.
- 11.2.5 KEY STRATEGIES
11.3 JUBILANT PHARMA LIMITED
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCTS/SERVICES OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 KEY STRATEGIES
11.4 LINGIT AS
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 PRODUCTS OFFERED
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 KEY STRATEGIES
11.5 SOLI
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 PRODUCTS OFFERED
- 11.5.4 KEY DEVELOPMENTS
- 11.5.5 KEY STRATEGIES
11.6 NOVARTIS AG
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS/SERVICES OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 SWOT ANALYSIS
- 11.6.6 KEY STRATEGIES
11.7 LYFTA
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL OVERVIEW
- 11.7.3 PRODUCTS/SERVICES OFFERED
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 KEY STRATEGIES
11.8 GLAXOSMITHKLINE
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 FINANCIAL OVERVIEW
- 11.8.3 PRODUCTS OFFERED
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 SWOT ANALYSIS
- 11.8.6 KEY STRATEGIES
11.9 TEVA PHARMACEUTICAL INDUSTRIES LTD.
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL OVERVIEW
- 11.9.3 PRODUCTS/SERVICES OFFERED
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 SWOT ANALYSIS
- 11.9.6 KEY STRATEGIES
11.10 ELI LILLY & COMPANY
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL OVERVIEW
- 11.10.3 PRODUCTS/SERVICES OFFERED
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 SWOT ANALYSIS
- 11.10.6 KEY STRATEGIES
11.11 RPG LIFE SCIENCES LTD
- 11.11.1 COMPANY OVERVIEW
- 11.11.2 FINANCIAL OVERVIEW
- 11.11.3 PRODUCTS/SERVICES OFFERED
- 11.11.4 KEY DEVELOPMENTS
- 11.11.5 KEY STRATEGIES
11.12 HOPALAI D.O.O.
- 11.12.1 COMPANY OVERVIEW
- 11.12.2 FINANCIAL OVERVIEW
- 11.12.3 PRODUCTS/SERVICES OFFERED
- 11.12.4 KEY DEVELOPMENTS
- 11.12.5 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES
12.2 RELATED REPORTS